iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Aurobindo Pharma gets Form 483 with 10 observations from USFDA

19 Nov 2022 , 03:20 PM

The drug maker said that the unit – IX, an intermediate facility situated at Gundlamachnoor Village, Sangareddy District, Telangana had been classified as OAI (official action indicated) on 17 May 2019 and the company had responded to the agency and carried out the required corrective actions. The US drug regulator reinspected the facility from 10 November 2022 to 18 November 2022. At the end of the inspection, the pharmaceutical company was issued a Form 483 with 10 observations. The observation is procedural in nature and not related to data integrity, the pharma company stated. The pharma major added that it will respond to the US FDA, within the stipulated timeline and shall work closely with the agency to address the observations at the earliest. Aurobindo Pharma develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. The pharmaceutical company reported 41.3% fall in consolidated net profit to Rs 409.45 crore on a 3.7% decline in net sales to Rs 5,673.65 in Q2 FY23 over Q2 FY22. Shares of Aurobindo Pharma were down 1.13% to Rs 468.75 on Friday, 18 November 2022. Powered by Capital Market – Live News

Related Tags

  • capital market
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Most Read News

Top Stocks for Today - 25th April 2025
25 Apr 2025|06:47 AM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.